MX383558B - Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco - Google Patents

Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco

Info

Publication number
MX383558B
MX383558B MX2018001686A MX2018001686A MX383558B MX 383558 B MX383558 B MX 383558B MX 2018001686 A MX2018001686 A MX 2018001686A MX 2018001686 A MX2018001686 A MX 2018001686A MX 383558 B MX383558 B MX 383558B
Authority
MX
Mexico
Prior art keywords
capped
adcs
antibodies
antibody
uncapped
Prior art date
Application number
MX2018001686A
Other languages
English (en)
Other versions
MX2018001686A (es
Inventor
Amarnauth Shastrie Prashad
Leo Joseph Letendre
Ronald William Kriz
Tao He
Wenge Wang
Will Somers
Xiaotian Zhong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018001686A publication Critical patent/MX2018001686A/es
Publication of MX383558B publication Critical patent/MX383558B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un proceso de producción de anticuerpo en células de mamífero en donde residuos de cisteína sin par manipulados se modifican y tapan de forma post - transferente con entidades químicas particulares, los cuales anticuerpos con capuchón son bien adecuados para más pasos de conjugación específicos de sitio para formar conjugados de anticuerpo- fármaco (ADCs) o conjugados de proteína fármaco; los ADCs producidos usando estos anticuerpos con capuchón incluyendo e n par t i c u lar ADCs formados por la reducción selectiva de los residuos de cisteína de los anticuerpos con capuchón, y los ADCs formados usando mangos químicos tales como grupos biortogonales de aldehído/azida/alquino, que permiten química de conjugación de fármaco adicional ; y anticuerpos sin capuchón producido s por células en medio de cisteína, cistina y glutationa bajo, y ADCs producidos vía conjugación di recta a estos anticuerpos sin capuchón.
MX2018001686A 2015-08-12 2016-08-09 Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco MX383558B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562204005P 2015-08-12 2015-08-12
PCT/IB2016/054789 WO2017025897A2 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Publications (2)

Publication Number Publication Date
MX2018001686A MX2018001686A (es) 2019-01-31
MX383558B true MX383558B (es) 2025-03-14

Family

ID=56855760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001686A MX383558B (es) 2015-08-12 2016-08-09 Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco

Country Status (18)

Country Link
US (2) US10653794B2 (es)
EP (2) EP3808768A1 (es)
JP (2) JP6865209B2 (es)
KR (2) KR102146617B1 (es)
CN (1) CN107849121B (es)
AU (1) AU2016305331B2 (es)
CA (1) CA2938333A1 (es)
DK (1) DK3334760T3 (es)
ES (1) ES2864842T3 (es)
HR (1) HRP20210579T1 (es)
HU (1) HUE053956T2 (es)
IL (1) IL257420B (es)
MX (1) MX383558B (es)
PL (1) PL3334760T3 (es)
PT (1) PT3334760T (es)
RU (2) RU2742260C2 (es)
SI (1) SI3334760T1 (es)
WO (1) WO2017025897A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938333A1 (en) * 2015-08-12 2017-02-12 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
US20230010108A1 (en) * 2018-10-12 2023-01-12 Hangzhou Dac Biotech Co., Ltd. A conjugation linker containing 2,3-diaminosuccinyl group
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
AU2020240310A1 (en) * 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
CN116635416A (zh) * 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
AU2022258829A1 (en) * 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition
KR20260052949A (ko) * 2023-08-11 2026-04-20 암젠 인크 고체상 항체 접합 방법
WO2026071051A1 (ja) * 2024-09-27 2026-04-02 東レ株式会社 免疫グロブリンまたはその抗原結合性断片のキャップ除去のための還元剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2003048357A1 (fr) * 2001-12-04 2003-06-12 Mitsubishi Pharma Corporation Procede d'activation de proteine
US8633300B2 (en) * 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP2021397A4 (en) * 2006-05-26 2012-01-04 Ipsen Pharma PROCESS FOR POTENTIAL PEGYLATION
US8612161B2 (en) * 2008-03-19 2013-12-17 Intelligent Biosystems Inc. Methods and compositions for base calling nucleic acids
EP2586788B1 (en) * 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2483289B2 (en) * 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
CA2781682A1 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
RU2661764C2 (ru) * 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp
RU2582259C2 (ru) * 2012-02-24 2016-04-20 Алтеоген Инк. Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения
WO2014052650A2 (en) 2012-09-26 2014-04-03 Massachusetts Institute Of Technology Modification of peptides via snar reactions of thiols with fluorinated aromatics
RU2016119491A (ru) * 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
EP3077522A1 (en) * 2013-12-04 2016-10-12 Immunogen, Inc. Compositions and methods for antibody production
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
KR102046862B1 (ko) 2015-03-20 2019-11-20 화이자 인코포레이티드 Cti 약물작용발생단을 함유하는 이관능성 세포독성제
CA2938333A1 (en) * 2015-08-12 2017-02-12 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Also Published As

Publication number Publication date
BR112018001904A2 (pt) 2018-09-18
RU2018105128A3 (es) 2020-07-27
CA2938333A1 (en) 2017-02-12
JP6865209B2 (ja) 2021-04-28
HRP20210579T1 (hr) 2021-05-28
KR102319622B1 (ko) 2021-11-02
MX2018001686A (es) 2019-01-31
ES2864842T3 (es) 2021-10-14
RU2021101009A (ru) 2021-02-20
US20200230256A1 (en) 2020-07-23
US20190030183A1 (en) 2019-01-31
SI3334760T1 (sl) 2021-07-30
IL257420B (en) 2022-08-01
US10653794B2 (en) 2020-05-19
EP3334760B1 (en) 2021-03-10
RU2018105128A (ru) 2019-09-12
HUE053956T2 (hu) 2021-08-30
EP3808768A1 (en) 2021-04-21
WO2017025897A2 (en) 2017-02-16
PL3334760T3 (pl) 2021-10-11
CN107849121B (zh) 2021-11-09
JP2018525990A (ja) 2018-09-13
JP2021118694A (ja) 2021-08-12
KR20180038041A (ko) 2018-04-13
PT3334760T (pt) 2021-04-23
CN107849121A (zh) 2018-03-27
HK1252799A1 (zh) 2019-06-06
AU2016305331A1 (en) 2018-02-15
IL257420A (en) 2018-06-28
DK3334760T3 (da) 2021-04-19
RU2742260C2 (ru) 2021-02-04
AU2016305331B2 (en) 2019-05-16
EP3334760A2 (en) 2018-06-20
US11980669B2 (en) 2024-05-14
KR20200100850A (ko) 2020-08-26
WO2017025897A3 (en) 2017-04-06
KR102146617B1 (ko) 2020-08-20

Similar Documents

Publication Publication Date Title
WO2017025897A3 (en) Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
Cai et al. Neoproterozoic subduction along the Ailaoshan zone, South China: Geochronological and geochemical evidence from amphibolite
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
Sandvig et al. Lipid requirements for entry of protein toxins into cells
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
EP4653013A3 (en) Methods and compositions for modified t cells
MY176822A (en) Anti-pd-1 antibody and use thereof
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
MX2018011383A (es) Replicon de arn para la expresion genica versatil y eficiente.
PE20200839A1 (es) Anticuerpos anti-cd137
SA520411849B1 (ar) أجسام مضادة ومتقارنات جسم مضاد مع عقار نوعية من أجل cd123 واستخداماتها
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
PH12019502730A1 (en) Method of manufacturing bispecific antibodies and therapeutic use of such antibodies
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
PE20161324A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
MX2020002791A (es) Reduccion selectiva de proteinas.
TW200833713A (en) Human antibodies that bind CD19 and uses thereof
SG10201807736SA (en) Composition and method for stabilizing nucleic acids in biological samples
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
MY197322A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
WO2014204988A3 (en) 5t4-targeted immunofusion molecule and methods
WO2017070654A8 (en) Programmable universal cell receptors and methods of using the same